全文获取类型
收费全文 | 1874篇 |
免费 | 115篇 |
国内免费 | 75篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 55篇 |
妇产科学 | 18篇 |
基础医学 | 233篇 |
口腔科学 | 22篇 |
临床医学 | 241篇 |
内科学 | 378篇 |
皮肤病学 | 35篇 |
神经病学 | 45篇 |
特种医学 | 260篇 |
外科学 | 81篇 |
综合类 | 30篇 |
一般理论 | 1篇 |
预防医学 | 116篇 |
眼科学 | 28篇 |
药学 | 128篇 |
中国医学 | 4篇 |
肿瘤学 | 384篇 |
出版年
2023年 | 7篇 |
2022年 | 7篇 |
2021年 | 11篇 |
2020年 | 9篇 |
2019年 | 16篇 |
2018年 | 21篇 |
2017年 | 11篇 |
2016年 | 22篇 |
2015年 | 27篇 |
2014年 | 40篇 |
2013年 | 38篇 |
2012年 | 63篇 |
2011年 | 59篇 |
2010年 | 71篇 |
2009年 | 75篇 |
2008年 | 68篇 |
2007年 | 91篇 |
2006年 | 61篇 |
2005年 | 79篇 |
2004年 | 64篇 |
2003年 | 80篇 |
2002年 | 71篇 |
2001年 | 64篇 |
2000年 | 87篇 |
1999年 | 61篇 |
1998年 | 106篇 |
1997年 | 91篇 |
1996年 | 87篇 |
1995年 | 64篇 |
1994年 | 64篇 |
1993年 | 51篇 |
1992年 | 31篇 |
1991年 | 28篇 |
1990年 | 33篇 |
1989年 | 37篇 |
1988年 | 42篇 |
1987年 | 36篇 |
1986年 | 28篇 |
1985年 | 25篇 |
1984年 | 22篇 |
1983年 | 12篇 |
1982年 | 20篇 |
1981年 | 11篇 |
1980年 | 13篇 |
1979年 | 5篇 |
1978年 | 6篇 |
1977年 | 16篇 |
1976年 | 13篇 |
1975年 | 13篇 |
1900年 | 2篇 |
排序方式: 共有2064条查询结果,搜索用时 15 毫秒
1.
P Avalos-Peralta† A Herrera† JJ Ríos-Martín‡ AM Pérez-Bernal† D Moreno-Ramírez† F Camacho† 《Journal of the European Academy of Dermatology and Venereology》2006,20(1):79-83
We report the case of a patient with a 13-year history of pemphigus vulgaris (PV) treated with immunosuppressive agents, prednisone and mycophenolate mofetil who had developed lesions of Kaposi's sarcoma (KS) on a sole plaque of PV that had been previously treated with intralesional injections of steroids. The lesions were surgically removed and polymerase chain reaction (PCR) demonstrated human herpesvirus-8 (HHV-8) DNA. There were neither recurrences nor later dissemination of KS following gradual decrease of the immunosuppressive therapy. We suggest that the treatment with intralesional steroids may have influenced the local reactivation of a latent infection of the virus, determining the appearance of this localized KS. 相似文献
2.
CM Reid M. Nelson P. Beckinsale P. Ryan LMH Wing LJ Beilin MA Brown GLR Jennings CI Johnston J. Marley JJ McNeil TO Morgan J. Shaw ID Steven MJ West 《Clinical and experimental pharmacology & physiology》1997,24(5):370-373
1. The present study aimed to determine the feasibility of conducting a 5 year cardiovascular outcome trial of the treatment of 6000 elderly hypertensive patients in Australian general practices. 2. General practitioners (GPs) were invited to participate by mail and personal follow-up. Patient records were reviewed to identify subjects for a blood pressure (BP) screening programme. Blood pressure was measured on three occasions and eligible subjects were included if the average BP was 160 mmHg systolic or 90 mmHg diastolic if systolic BP was 140 mmHg. 3. Seven hundred and forty-one GPs were approached and 89 were enrolled in the study (12% of mail invites and 75% of those receiving a personal contact). In 16 practices where screening was completed, 82 000 records were reviewed to identify 4% patients eligible for screening. Twenty-two per cent of eligible subjects attended screening. Of 1938 subjects screened, 180 (9%) had BP 5=160/90 mmHg. Forty-seven percent of subjects (n = 916) were receiving antihypertensive therapy and 184 (20%) were withdrawn from therapy. One hundred and sixteen (63%) of these subjects had BP return to study entry levels within 6 weeks. Fifty-seven newly diagnosed and 81 previously treated subjects were randomized (7% of the screened population). 4. Based on the high participation rate of GPs, the response rate of patients to attend a BP screening programme and the 7% randomization to screening ratio for entry into the study, the ANBP2 pilot study has demonstrated that it is feasible to recruit subjects from Australian general practices to a cardiovascular outcome trial. 相似文献
3.
4.
Dabis Maleate (1,4-bis(2'-chloroethyl)-1,4-diazabicyclo[2.2.1] Heptane dihydrogen dimaleate) (NSC 262666) is an alkylating quaternary nitrogen compound. In a previous phase I study using a once-every-3-weeks administration the dose-limiting toxicity was neurotoxicity and the recommended dose for phase II studies was 750 mg/m2 iv every 3 weeks. In vitro studies suggested a higher activity after more frequent administration, and in vivo studies a better therapeutic index with prolonged infusion. We studied 11 patients with solid tumors. Dose levels tested ranged from 250-750 mg/m2, either as a day 1-3 regimen or weekly, the latter as bolus administration or as prolonged infusion. The dose-limiting toxicity was neurotoxicity consisting of paresthesias and ataxia. Nausea and vomiting were moderate. No other major toxicity was observed. The dose recommended for phase II studies is 500 mg/m2/week as a 6-hour iv infusion for 6 weeks, followed by a 3-week rest period. 相似文献
5.
S B Kaye J Wanders M Clavel J Verweij M J Piccart J F Smyth W W Ten Bokkel Huinink D J Wagener I R Judson F Cavalli 《Annals of oncology》1992,3(5):406-408
A total of 91 eligible patients with metastatic cancer have been treated in a series of phase II trials of the novel pentacyclic pyrroloquinone, fosquidone. Tumour types were breast (24), ovary (25), head and neck (21) and melanoma (21). All patients, except those with melanoma had received prior chemotherapy. The drug was given intravenously as a 20 min infusion, at the dose of 120 mg/m2 on days 1 to 5 of a 3 week cycle. Treatment was well tolerated; the only significant side-effects being mild headaches and generalised musculo-skeletal pains. Response was assessed after 2 cycles of therapy. Only one patient (with head and neck cancer) achieved an objective partial response, lasting 6 weeks. A total of 12 patients demonstrated stable disease for a median duration of 15 to 20 weeks. Using this schedule of administration, fosquidone has no significant antitumour activity in this group of tumours. 相似文献
6.
7.
A. S. Planting M. E. van der Burg M. de Boer-Dennert G. Stoter J. Verweij 《British journal of cancer》1993,68(4):789-792
Twenty-five patients with advanced solid tumours were entered in a phase I/II study of six, weekly cycles of cisplatin. Nineteen patients were chemonaive and six were previously treated. The starting dose was 50 mg m-2 week-1. This dose could be escalated without major toxicity to 70 mg m-2 week-1. At a dose of 80 mg m-2 myelosuppression grade 3 occurred as well as grade 1 nephro- and neurotoxicity. The maximum tolerated dose was 85 mg m-2 with dose limiting thrombocytopenia. Hypertonic saline was effective in preventing nephrotoxicity. Ondansetron was a very effective antiemetic in the first weeks of treatment but its efficacy waned later on. Responses were observed in head and neck cancer, melanoma and mesothelioma. At the dose level of 80 mg m-2 the optimal dose intensity was reached. This schedule will be tested further in phase II studies. 相似文献
8.
SUMMARY A young patient presenting with splenomegaly and hypersplenism was inadvertently found to have selective IgA deficiency. There were no symptoms of immunodeficiency and the patient responded well to splenectomy, with return of blood counts to normal without adverse effects. No other cause for the hypersplenism was found. We postulate selective IgA deficiency as a cause of splenomegaly and hypersplenism. 相似文献
9.
J H Schornagel J Verweij P H de Mulder F Cognetti J B Vermorken P Cappelaere J P Armand J Wildiers M Clavel A Kirkpatrick 《Annals of oncology》1992,3(3):223-226
Forty-seven patients with advanced and/or recurrent squamous cell carcinoma of the head and neck were treated with 10-ethyl-10-deaza-aminopterin (10-EdAM), a new analogue of methotrexate. The drug was given as a weekly i.v. bolus injection, starting at 80 mg/m2 with two dose increments of 10% if no toxicity was observed after two weeks. Only patients with tumors of the larynx, oral cavity, oropharynx and hypopharynx were included in the trial. Eighty-two percent of the patients had had prior surgery and/or radiotherapy. Forty-four patients were evaluable for response and toxicity. Five CR (12%) and five PR were obtained, yielding a response rate of 24% (CR+PR). The toxicity was similar to that usually seen with methotrexate; stomatitis and skin toxicity were rather pronounced. The data suggest that 10-EdAM has activity similar to that of methotrexate in patients with head and neck cancer. 相似文献
10.
P. H. E. Hilkens J. Verweij Ch. J. Vecht G. Stoter M. J. van den Bent 《Annals of oncology》1997,8(2):187-190
Background: Docetaxel, a semi-synthetic taxane may cause a usuallymild sensory neuropathy. We describe the clinical characteristics of fivepatients who developed a more severe neuropathy following treatment withdocetaxel.Patients and methods: All patients were treated in phase II studieswith 100 mg/m2 docetaxel in three weekly cycles, withoutsteroid administration.Results: The clinical picture in these patients was dominated by asensory neuropathy, but in one case severe weakness was present. Anotherpatient developed Lhermitte's sign. Signs and symptoms are usually reversibleafter discontinuation of docetaxel administration, but in three patientssymptoms worsened for some time after the end of treatment before improvementoccurred.Conclusion: Severe docetaxel neuropathy may especially occurfollowing treatment with cumulative dosage over 600 mg/m2; inpatients treated with this dosage a moderate or severe neuropathy may not berare. 相似文献